Barnaby began his career at Goldman Sachs in London as an equity research analyst before working for Credit Agricole in Hong Kong. He has more than twenty years of private equity investment experience in the technology sector. In addition to being an active investor he has also founded several successful technology businesses. He is a founding partner in GT Capital, a specialist Hong Kong based healthcare technology investment business, and founding partner of Oxford Investment Consultants.
Barnaby holds a BA Honours degree from Brasenose College, University of Oxford and has written for the Daily Telegraph on business and economics.
Yew Lin Goh
Yew Lin Goh has been the Managing Director of G. K. Goh Holdings Ltd. since March 1, 2008 and its Executive Director since March 28, 1990. He joined the GK Goh Group in 1984 after working for Robert Fleming & Co Ltd in London. He has also been a non-executive director on the Board of Temasek Holdings Pte Ltd since August 2005. He is presently the Chairman of Seatown Holdings Pte Ltd, and Deputy Chairman of the National Arts Council. He is also a member of the National University of Singapore Board of Trustees and Chairman-Designate of the Duke-NUS Graduate School of Medicine. Mr Goh holds a Bachelor of Science (Economics) degree from the University of Pennsylvania’s Wharton School.
Professor John Mattick
John was CEO of Genomics England until February this year. He obtained his BSc with First Class Honours from the University of Sydney and his PhD from Monash University. He undertook his postdoctoral training at the Texas Medical Center in Houston and then joined the CSIRO Division of Molecular Biology in Sydney where he developed one of the first genetically engineered vaccines. In 1988 he was appointed the Foundation Professor of Molecular Biology at the University of Queensland, where he was also Foundation Director of the ARC Special Research Centre for Molecular and Cellular Biology, the Institute for Molecular Bioscience and the Australian Genome Research Facility, as well as ARC Federation Fellow and NHMRC Australia Fellow. He also spent sabbatical periods at the Universities of Cambridge, Oxford, Cologne and Strasbourg. In 2012 he returned to Sydney to take up the position of Executive Director of the Garvan Institute of Medical Research.
Professor Matthew Wood
Matthew is one of the UK’s senior scientists. Matthew researches gene therapy for degenerative disorders of the nervous system and muscle. His research focuses on new therapeutic approaches, targeting messenger RNA. This has the potential to allow us to repair genetic defects and target the specific genes which cause diseases such as Duchenne muscular dystrophy. He also investigates the ways RNA interference, or RNAi, could be used to "silence" genes which cause disease, both in muscle and in the nervous system. In particular, RNAi has great potential for use in treating neurodegenerative disorders such as Parkinson’s disease.
Matthew has been an advisor to the Gene Therapy Advisory Committee, UK, and scientific advisor to Parkinson's UK, Action Duchenne, Muscular Dystrophy Campaign, Novartis, and Sirna Therapeutics. Matthew is interim director of the brand new UK Nucleic Acids Institute, located at Harwell: The Rosalind Franklin Institute.
Alex is a founding partner of RT with Barnaby. Alex has experience investing across early to late-stage Venture Capital, in Oxford, London and Cambridge (previously also in the US) and has led investments into synthetic biology, genomics and data-focussed drug discovery and currently sits on the board of Nuclera, Polyprox and Resurgo Genetics. Prior to RT, Alex founded, invested in, and has advised several businesses in the tech and biotech sector including mandated advisory roles on fundraisings conducted alongside Barnaby Martin. Although trained as an IP and Corporate Finance lawyer, at JAG Shaw Baker and Erksine Chambers, Alex left the field to start a e-commerce platform business in 2011. He holds an LL.B (hons) degree in English Law from University College London.
After reading English Literature at Hertford College, Oxford (1975-78) Nick Harbinson joined John Swire and Sos, and was posted to New Guinea and then Hong Kong where he worked in the shipping agency division. In 1983 he began his career in Asian institutional equity sales on the London desk of WI Carr Overseas. In 1985 he was transferred to the Asian equity desk in New York with WI Carr, where he worked, after a brief flirtation with Swiss Bank Corporation in 1987, until the end of 1988 when he returned to Hong Kong with WI Carr. In 1990 he was appointed managing director with responsibility for WI Carr’s Asian ex-Japan equity business. In 1993 he joined Goldman Sachs as co-head of Asian Equities, based in Hong Kong. In February 1995 he returned to WI Carr as Chief Executive Officer, a position he occupied until April 2000. In July 2000 Nick joined Merrill Lynch where he had responsibility for Asian sales and sales-trading, based in Singapore. He left Merrill Lynch in April 2003 to found Tantallon Capital.
Simon brings to RT his considerable experience in client management and investor relations. He joins from the £770 Bn asset manager T. Rowe Price, where he managed their UK Discretionary Client Relationship team. Prior to that, Simon helped raise £880m for Patient Capital Trust (WPCT.L), the early stage UK technology fund managed by Neil Woodford. He spent over a decade before that at Thames River Capital / F&C, having started his career at Cazenove as a marketing executive.
Max undertook his Phd at the Weatherall Institute of Medicine, focusing on using next-generation screening technologies such as CRISPR-Cas9 to develop combination therapies for leukemia. Max holds a BA in Biological Natural Sciences and an MPhil in Bioscience Enterprise (MBE), from the University of Cambridge. He was an R&D intern at Gen9 Bio, a Boston-based next-generation DNA synthesis startup, and has experience providing consulting work for IMS/IQVIA and Cambridge Consultants, alongside a tech consultancy with Microsoft Research.